No Data
No Data
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $39 From $42
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
Sobi and Enable Injections Announce Agreement to Develop and Distribute Aspaveli in Combination With EnFuse in Sobi Territories
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
108S OP : Best pharma stock to buy now